ACAD
ACADIA Pharmaceuticals Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.04
+0.64%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.1B | 1.1B | 957.8M | 726.4M | 517.2M |
| Cost of Revenue | 101.0M | 89.0M | 81.8M | 45.7M | 10.2M |
| Gross Profit | 1.0B | 982.5M | 876.0M | 680.7M | 507.1M |
| Operating Expenses | |||||
| R&D Expense | 331.0M | 328.8M | 303.2M | 351.6M | 361.6M |
| SG&A Expense | 620.3M | 548.9M | 488.4M | 402.5M | 369.1M |
| General & Admin Expense | 160.3M | — | — | 393.1M | — |
| Selling & Marketing Expense | — | — | — | 9.4M | — |
| Other Expenses | — | — | (146.5M) | — | — |
| Total Operating Expenses | 951.3M | 877.7M | 645.2M | 754.1M | 730.7M |
| Cost and Expenses | 1.1B | 966.7M | 727.0M | 799.8M | 740.8M |
| Operating Income (EBIT) | 86.4M | 104.8M | 230.8M | (73.4M) | (223.6M) |
| Non-Operating | |||||
| Interest Income | 32.6M | 31.7M | 25.5M | 17.2M | 6.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 32.6M | 31.7M | 25.5M | 17.2M | 6.6M |
| Other Non-Op Income/Expense | 35.0M | 34.1M | 27.3M | 22.3M | 10.2M |
| Non-Operating Income (excl Interest) | (17.7M) | (34.1M) | 146.5M | (22.3M) | (10.2M) |
| EBT (Pre-Tax Income) | 121.4M | 138.9M | 258.1M | (51.0M) | (213.4M) |
| Income Tax Expense | (259.1M) | (252.1M) | 31.6M | 10.3M | 2.5M |
| Bottom Line | |||||
| Net Income | 380.5M | 391.0M | 226.5M | (61.3M) | (216.0M) |
| Earnings from Cont. Ops | 380.5M | 391.0M | 226.5M | (61.3M) | (216.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 380.5M | 391.0M | 226.5M | (61.3M) | (216.0M) |
| Per Share | |||||
| Basic EPS | $2.25 | $2.32 | $1.37 | ($0.37) | ($1.34) |
| Diluted EPS | $2.22 | $2.29 | $1.36 | ($0.37) | ($1.34) |
| Revenue Per Share | $6.64 | $6.33 | $5.78 | $4.43 | $3.20 |
| Shares | |||||
| Basic Shares Outstanding | 171.6M | 169.3M | 165.7M | 163.8M | 161.7M |
| Diluted Shares Outstanding | 172.9M | 171.4M | 166.4M | 163.8M | 161.7M |
| Profitability Metrics | |||||
| EBITDA | 116.1M | 150.7M | 100.2M | (45.5M) | (211.4M) |
| D&A | 12.0M | 11.8M | 15.9M | 5.6M | 2.0M |
| EBIT | 104.1M | 138.9M | 84.3M | (51.0M) | (213.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026